BLRX Valuation

BioLine RX Ltd

Add to Watchlist

Advanced Chart

4.490

+0.13(2.982%)1D

Overview
Forecast
Valuation
Earnings

BLRX Relative Valuation

BLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BLRX is overvalued; if below, it's undervalued.

Historical Valuation

BioLine RX Ltd (BLRX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4.96 is considered Overvalued compared with the five-year average of -1.44. The fair price of BioLine RX Ltd (BLRX) is between 1.57 to 3.20 according to relative valuation methord. Compared to the current price of 4.49 USD , BioLine RX Ltd is Overvalued By 40.37%.

Relative Value

Fair Zone

1.57-3.20

Current Price：4.49

40.37%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

466.61

P/B

Median3y

68.43

Median5y

41.76

-170.12

FCF Yield

Median3y

-88.72

Median5y

-65.65

Competitors Valuation Multiple

The average P/S ratio for BLRX's competitors is 2.18, providing a benchmark for relative valuation. BioLine RX Ltd Corp (BLRX) exhibits a P/S ratio of 4.96, which is 127.08% above the industry average. Given its robust revenue growth of -96.28%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap